Key Summary Points {#FPar1}
==================

This systematic literature review analyzed the available literature on the clinical, economic, and humanistic burden of delayed diagnosis among patients with axial spondyloarthritis (axSpA).Overall, patients with delayed diagnosis of axSpA had worse clinical outcomes, including higher disease activity, worse physical function, and more structural damage, compared with patients who had an earlier diagnosisMoreover, patients with a delayed diagnosis had higher healthcare costs and greater likelihood of work disability compared with those with an earlier diagnosis.Delayed diagnosis was largely associated with worse quality of life, including greater likelihood for depression and negative psychological impact.Our study emphasizes the value of early recognition of axSpA to enhance clinical outcomes and improve patient and societal burden.

Plain Language Summary {#Sec1}
======================

Axial spondyloarthritis (axSpA) is a chronic inflammatory disease that primarily affects the spine and can cause chronic back pain and damage to the spinal vertebrae. AxSpA can also cause joint pain, stiffness, fatigue, and reduced physical function, which may lead to considerable physical, economic, and emotional burden. There is often a substantial delay between symptom onset and axSpA diagnosis due to the difficulty of distinguishing back pain associated with axSpA from other forms of back pain, lack of well-established criteria for diagnosis, patient delay in seeking care, and delayed referral of patients to specialists. Delayed diagnosis postpones treatment and disease management, which may result in irreversible structural damage, higher healthcare costs, work disability, and worse health-related quality of life.

Few studies have evaluated the overall impact of delayed diagnosis of axSpA on the burden of disease. This systematic review evaluated the available evidence on the clinical, economic, and humanistic burden associated with delayed diagnosis of axSpA to provide a comprehensive overview of the impact on overall disease burden. Data from 21 relevant studies indicated that patients with delayed diagnosis of axSpA had worse clinical outcomes, including higher disease activity, worse physical function, and more structural damage; higher healthcare costs; greater likelihood of work disability; and worse quality of life, including greater likelihood for depression and negative psychological impact, compared with those who had an earlier diagnosis. This study highlights the importance of early recognition of axSpA to improve outcomes and reduce extensive burden on patients and society.

Introduction {#Sec2}
============

Axial spondyloarthritis (axSpA) is a chronic, inflammatory rheumatic disease that primarily affects the axial skeleton \[[@CR1]\]. AxSpA encompasses both patients with radiographic sacroiliitis visible on imaging (ankylosing spondylitis \[AS\]) and those without evidence of radiographic damage in the sacroiliac joints (nonradiographic axSpA). AxSpA is characterized by inflammation of the spinal vertebrae that causes chronic back pain and stiffness and may lead to fusion of vertebral joints. Additionally, axSpA frequently affects the peripheral joints and entheses and is associated with extra-articular manifestations, including uveitis, psoriasis, and inflammatory bowel disease \[[@CR1], [@CR2]\]; if left unmanaged, axSpA may lead to irreversible structural damage and reduced spinal mobility. Patients with axSpA can experience considerable physical, economic, and emotional burden due to the pain, fatigue, and impaired physical function resulting from the disease \[[@CR3]--[@CR5]\]. Therefore, early diagnosis and treatment before irreversible changes occur are crucial for managing patients with axSpA.

However, there is often a substantial delay between symptom onset and axSpA diagnosis, with recent reports suggesting an average diagnostic delay of 5--14 years \[[@CR6]--[@CR11]\]. One factor contributing to the delay in diagnosis of axSpA is the difficulty in distinguishing inflammatory back pain (IBP), a key symptom of axSpA that affects the spine and sacroiliac joints \[[@CR12], [@CR13]\], from other highly prevalent forms of low back pain in the general population---the overall global prevalence of low back pain is approximately 9% \[[@CR14]\], and up to 80% of adults will experience low back pain in their lifetime \[[@CR15], [@CR16]\]. Additionally, chronic (\> 3 months) back pain is a common symptom among several conditions seen in primary care \[[@CR17], [@CR18]\]; prevalence estimates of chronic low back pain vary by country and range from 4 to 24% \[[@CR19]\]. In contrast, the prevalence of AS ranges from 0.01 to 0.54%; among the few studies that have evaluated the prevalence of axSpA in general, prevalence ranges from 0.13 to 1.40% \[[@CR20]--[@CR22]\]. Thus, IBP due to axSpA may be mistaken for chronic back pain associated with other more common disorders, particularly in patients without clear radiographic sacroiliitis \[[@CR23]\].

Another factor contributing to delayed diagnosis is the lack of well-established diagnostic criteria that encompass both AS and nonradiographic axSpA and can be routinely applied in clinical practice. Historically, AS was considered the typical axSpA disease state and was thus the primary focus of classification criteria \[[@CR21]\]. The Rome criteria developed in 1961, the New York criteria published in 1966, and the 1984 modified New York criteria require definite sacroiliitis visible on radiographs for classification of AS \[[@CR24], [@CR25]\]. However, radiographic sacroiliitis may take years to develop or may not develop at all \[[@CR26], [@CR27]\], and these criteria therefore do not capture many patients with early AS or nonradiographic axSpA. The Amor criteria (1990) \[[@CR28]\] and European Spondyloarthropathy Study Group criteria (1991) \[[@CR29]\] include but do not require radiographic sacroiliitis; although these criteria have been applied for classification of patients with axSpA, they were developed for spondyloarthritis (SpA) in general and emphasize peripheral features of SpA, which may result in misclassification of patients with limited axial involvement.

To better differentiate axSpA from peripheral SpA and allow for the classification of nonradiographic axSpA, the Assessment of SpondyloArthritis International Society (ASAS) developed updated classification criteria for the identification of axSpA in 2009 \[[@CR30], [@CR31]\]. Patients must have ≥ 3 months of back pain, age of onset \< 45 years, and radiographic sacroiliitis on imaging with ≥ 1 SpA feature or HLA-B27 positivity and ≥ 2 SpA features. SpA features include IBP, arthritis, enthesitis, uveitis, dactylitis, psoriasis, Crohn\'s disease or ulcerative colitis, good response to nonsteroidal anti-inflammatory drugs, HLA-B27 positivity, and elevated C-reactive protein (CRP) levels. Overall, the ASAS criteria have good sensitivity and specificity for the classification of axSpA \[[@CR31], [@CR32]\].

Although greater awareness of axSpA and the development and application of classification criteria have resulted in a decrease in the time to axSpA diagnosis \[[@CR33]--[@CR35]\], the above classification criteria were developed for clinical research and not as diagnostic tools; thus, use of these criteria for diagnosis of axSpA can be limited in routine clinical practice \[[@CR1], [@CR36], [@CR37]\]. Criteria such as IBP, good response to nonsteroidal anti-inflammatory drugs, and presence of enthesitis are somewhat subjective in nature \[[@CR36]\]. Development of radiographic sacroiliitis may be delayed \[[@CR26], [@CR27]\], and interpretation of radiographs of the sacroiliac joints is subject to substantial interreader variability \[[@CR38], [@CR39]\]. Current magnetic resonance imaging protocols routinely used in the evaluation of low back pain can yield false-negative results due to low sensitivity for inflammation or false-positive results due to inflammatory changes that can occur in the sacroiliac joints of athletes and patients with degenerative arthritis, trauma, or other conditions \[[@CR36], [@CR37], [@CR40]--[@CR42]\]. Additionally, use of these criteria may not be regularly applied in rheumatology settings \[[@CR43]\], and discrepancies have been observed between fulfillment of ASAS criteria and rheumatologist diagnosis of axSpA \[[@CR32]\].

The majority of patients eventually diagnosed with axSpA first seek care from primary care physicians or nonrheumatology healthcare providers \[[@CR7], [@CR36], [@CR43], [@CR44]\]. Prompt referral to rheumatologists can facilitate an earlier diagnosis \[[@CR36]\]. However, referral to rheumatology specialists is often delayed due to underrecognition of symptoms of IBP suggestive of axSpA among nonrheumatology healthcare providers \[[@CR36], [@CR44], [@CR45]\]. Lack of nearby specialists and long wait times may further inhibit timely referral of patients \[[@CR44], [@CR45]\]. Factors such as patient delay in seeking care, patient reluctance to see a specialist, and insurance restrictions may also contribute to diagnostic delay \[[@CR44]\]. Delayed diagnosis of axSpA results in delayed treatment and disease management, which may negatively impact disease prognosis and result in greater economic burden and worse health-related quality of life due to continued disease progression \[[@CR46]\]. Few studies have evaluated the impact of delayed diagnosis of axSpA on the overall burden of disease. The objective of this systematic review was to evaluate the available evidence on the clinical, economic, and humanistic burden associated with delayed diagnosis in patients with axSpA to provide a comprehensive overview of the impact of delayed diagnosis on overall disease burden.

Methods {#Sec3}
=======

Data Sources {#Sec4}
------------

This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines \[[@CR47]\]. We searched the MEDLINE Literature Analysis and Retrieval System Online (including MEDLINE In-Process) and *Excerpta Medica* (Embase) databases for original research articles (up to July 12, 2018) and conference abstracts (January 1, 2014, to July 12, 2018) reporting studies of delayed diagnosis of adult patients with axSpA associated with clinical, economic, or humanistic burden. The list of search terms is described in Supplementary Table 1. We also manually searched references cited in Cochrane reviews and/or systematic reviews identified during screening to identify any additional published literature not identified during the database searches. Additionally, abstract archives of the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting and the European League Against Rheumatism Annual European Congress of Rheumatology were searched to identify abstracts not yet indexed in Embase at the time of the search. This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

Eligibility Criteria and Article Selection {#Sec5}
------------------------------------------

Publications eligible for inclusion were English-language, noninterventional, original research studies of adult patients with axSpA that reported association of delayed axSpA diagnosis with clinical (e.g., comorbidities, mortality, disability, and functional status), economic (e.g., direct/indirect costs, resource use), or humanistic (e.g., health-related quality of life or utility measures) burden. The key inclusion and exclusion criteria are described in Table [1](#Tab1){ref-type="table"}.Table 1Details of systematic literature review methodologyDatabasesElectronic databases: MEDLINE, MEDLINE In-Process, and EmbaseConference databases: ACR/ARHP Annual Meeting and EULAR Annual European Congress of Rheumatology archivesTime frameFull-text articles: database start to July 12, 2018Conference abstracts: January 1, 2013, to July 12, 2018Inclusion criteriaPopulation: adult patients with axSpAOutcomes Clinical: comorbidities, mortality, and disability and functional status (e.g., BASDAI, BASFI, BASMI) Economic: direct/indirect costs, resource use data, type of cost data and value, and type of resource use and value Humanistic: HRQOL and utility values and qualitative measuresStudy design: original research studies, including observational studies; claims database studies; surveys; and any study reporting cost, resource use, and HRQOL dataExclusion criteriaAnimal/in vitro studies and studies with children or patients with peripheral spondyloarthritisNon-English-language articlesInterventional studies, including RCTs, nRCTs, or single-arm trialsHTAs, reviews, editorials, case reports, and case seriesCritical appraisal toolsDowns and Black Quality Index for assessing risk of bias \[[@CR48]\]Data extractionTotal number of patients analyzed, number of patients with outcome, mean, SD, SE, median, range, 95% CI, and *P* values, as applicable*ACR* American College of Rheumatology, *ARHP* Association of Rheumatology Health Professionals, *axSpA* axial spondyloarthritis, *BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BASFI* Bath Ankylosing Spondylitis Functional Index, *BASMI* Bath Ankylosing Spondylitis Metrology Index, *EULAR* European League Against Rheumatism, *HRQOL* health-related quality of life, *HTA* health technology assessment, *nRCT* nonrandomized controlled trial, *RCT* randomized controlled trial

Abstracts of all records retrieved from the literature search were screened for eligibility by two independent reviewers; any discrepancies were resolved by a third independent reviewer. Citations that did not match the eligibility criteria and duplicates of citations were excluded at the abstract-screening stage. Full-text publications of the included abstracts were retrieved and underwent second-level screening by two independent reviewers, and discrepancies were resolved by a third independent reviewer.

Data Extraction and Quality Assessment {#Sec6}
--------------------------------------

Data from the final list of included studies were extracted by one reviewer and validated by a second independent reviewer; any discrepancies were resolved by a third independent reviewer. For each included study, the study title, country, number of centers, total study population, objective, inclusion/exclusion criteria, follow-up duration, patient group populations, baseline patient data (age, sex, race, and disease duration), and authors' conclusions were extracted. Outcomes extracted to evaluate clinical burden included pain, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Metrology Index (BASMI), comorbidities, and disability. When available, laboratory values (e.g., CRP levels, erythrocyte sedimentation rate \[ESR\]) and measures of radiographic progression (e.g., Bath Ankylosing Spondylitis Radiology Index, modified Stoke Ankylosing Spondylitis Spine Score \[mSASSS\]), and spinal mobility (e.g., Schober test, occiput-to-wall distance) were also extracted. For assessment of economic burden, data on type and value of direct and indirect costs, resource utilization (e.g., number and length of hospital stays), and employment or disability were extracted. Outcomes extracted to evaluate humanistic burden included Ankylosing Spondylitis Quality of Life questionnaire (ASQOL) and the 36-item Short Form Health Survey.

For dichotomous outcomes, the data extracted were total number of patients analyzed and the number of patients with the outcome. For continuous outcomes, the data were extracted as number of patients, mean, SD, SE, median, range, 95% CI, and *P* values, as applicable.

The methodological quality of each study was evaluated using the Downs and Black Quality Index for assessing risk of bias \[[@CR48]\]. Briefly, study methodology was assessed using 26 questions evaluating characteristics of study reporting, external validity, and internal validity (bias and confounding) (Supplementary Table 2). The total possible score using this scale was 27, with higher numbers indicating higher methodological quality/lower risk of bias.

Results {#Sec7}
=======

Study Selection, Characteristics, and Quality Assessment {#Sec8}
--------------------------------------------------------

The initial search yielded 1391 citations, from which 21 studies were identified for inclusion after screening \[[@CR6], [@CR35], [@CR46], [@CR49]--[@CR66]\] (Fig. [1](#Fig1){ref-type="fig"}). Among the included studies, 15 reported clinical burden \[[@CR6], [@CR35], [@CR46], [@CR49]--[@CR52], [@CR55], [@CR59]--[@CR65]\], nine reported economic burden \[[@CR35], [@CR46], [@CR52], [@CR55]--[@CR58], [@CR62], [@CR66]\], and six reported humanistic burden \[[@CR6], [@CR53], [@CR54], [@CR62], [@CR65], [@CR66]\]; eight studies reported data on a combination of clinical, economic, and/or humanistic burden \[[@CR6], [@CR35], [@CR46], [@CR52], [@CR55], [@CR62], [@CR65], [@CR66]\], one of which reported data on all three outcomes \[[@CR62]\] (Fig. [2](#Fig2){ref-type="fig"}).Fig. 1PRISMA diagram for study selection. Searches were performed on July 12, 2018. *PRISMA*, Preferred Reporting Items for Systematic Reviews and Meta-Analyses. ^a^ Three studies had two publications eachFig. 2**A** Outcome types and **B** study designs of included studies. ^a^ Study references: clinical, 6, 35, 46, 49--52, 55, 59--65; economic, 35, 46, 52, 55--58, 62, 66; humanistic, 6, 53, 54, 62, 65, 66. ^b^ Study references: cross-sectional, 6, 35, 46, 49--51, 56, 58--60, 63, 66; retrospective observational, 52, 54, 55, 57, 61, 64; prospective observational, 62, 65; longitudinal cohort, 53

Study characteristics are described in Table [2](#Tab2){ref-type="table"}. The 21 included studies were published between 2009 and 2018 and were conducted in 13 countries: Argentina (*n* = 1), Australia (*n* = 1), China (*n* = 2), Egypt (*n* = 2), Korea (*n* = 1), India (*n* = 1), Iran (*n* = 2), Ireland (*n* = 3), Israel (*n* = 1), Italy (*n* = 1), Morocco (*n* = 1), Turkey (*n* = 3), and the United Kingdom (*n* = 2). The majority were cross-sectional (*n* = 12) or retrospective observational (*n* = 6) studies (Fig. [2](#Fig2){ref-type="fig"}). The number of study participants ranged from 10 to 1084 patients; the majority of studies (*n* = 17) included \< 200 patients, and one-third (*n* = 7) included \< 100 patients. Most studies (*n* = 15) included only patients with AS (Table [2](#Tab2){ref-type="table"}). Across all studies, the majority of patients (52.3--100%) were male, except one study in which the proportion of male patients was 35.1% \[[@CR57]\]. At the time of study participation, patients had a mean age of approximately 32--47 years and a mean disease duration of approximately 8--21 years. Among studies that reported age at symptom onset and/or diagnosis, mean age ranged from approximately 23--25 and 26--47 years, respectively. Mean diagnostic delay ranged from approximately 4--12 years.Table 2Characteristics of studies reporting impacts of delayed diagnosis in patients with axSpAStudyStudy designCountryPatient population \[*N*\]Male, %Age, mean (SD), years^a^Disease duration, mean (SD), yearsDiagnostic delay, mean (SD), yearsOutcomeNie A, et al. 2018Single center, cross-sectionalChinaAS\[281\]68.031.7 (9.8)7.9 (7.4)4.3 (5.3)ClinicalZhao J, et al. 2015Cross-sectionalChinaAS\[256\]88.3Onset: 22.9 (5.5)Diagnosis: 34.0 (8.3)10.1 (7.3)3.9 (2.0)ClinicalSeo MR, et al. 2015Cross-sectionalKoreaAxSpA\[94\]78.7Median (IQR)Enrollment: 40 (30--49)Onset: 23 (17--30)Diagnosis: 35 (24--43)Median (IQR)14 (8--21)Median (IQR)8 (3--15)Clinical, economicAggarwal R, et al. 2009Cross-sectionalIndiaAS\[70\]84.3Onset: 23.6 (8.8)Diagnosis: 32.5 ± 9.7NR6.9 (5.2)ClinicalGunasekera W, et al. 2014Retrospective observationalUKAS\[106\]79.0Onset: 24.5 (9.8)Diagnosis: 35.5 (14.0)NR10.5 (11.9)Clinical, economicMartindale J, Goodacre L. 2014Longitudinal cohortUKAS/AxSpA \[10\]70.040.2 (7.7)NRNRHumanisticFitzgerald G, et al. 2017Retrospective observationalIrelandAxSpA \[564\]78.247.1 (12.4)20.8 (12.2)8.6 (8.0)HumanisticSullivan C, et al. 2014Retrospective observationalIrelandAS\[92\]80.446.7 (range, 23--80)NR6.0 (4.8)Clinical, economicSullivan C, FitzGerald O. 2011Cross-sectionalIrelandAS\[59\]59.0Onset: 25Diagnosis: 32NR7.3 (range, 0--23)EconomicMennini FS, et al. 2018Retrospective observationalItalyAxSpA \[1084\]35.143.3 (NR)NRNREconomicAbdelrahman FI, Mortada M. 2018Cross-sectionalEgyptAxSpA\[126\]Before 2010: 87.5; After 2010: 80.0Diagnosis:Before 2010: 34.9 (6.4)After 2010: 25.8 (4.5)NRBefore 2010: 11.3 (3.9)After 2010: 4.6 (2.8)Clinical, economicAbdul-Sattar A, Abou El Magd S. 2017Cross-sectionalEgyptAS\[190\]94.437.8 (9.7)12.1 (8.9)6.3 (2.6)EconomicIbn YY, et al. 2012Cross-sectionalMoroccoAS\[100\]67.0Enrollment: 38.0 (13.0)Diagnosis: 32.7 (11.6)9.2 (6.8)4.1 (4.0)ClinicalFallahi S, Jamshidi AR. 2016Cross-sectionalIranAS\[163\]79.1Enrollment: 37.7 (9.9)Onset: 23.4 (7.1)Diagnosis: 31.3 (9.7)Median (IQR)12 (6--20)7.9 (7.2)Clinical, humanisticHajialilo M, et al. 2014Cross-sectionalIranAS\[60\]88.3Diagnosis: 36.4 (4.5)NR6.2 (3.5)ClinicalAlayli G, et al. 2015Retrospective observationalTurkeyAS\[85\]74.1Enrollment: 36.7 (11.0)Onset: 24.8 (8.8)Diagnosis: 29.9 (9.9)11.0 (5.6)5.1 (7.2)ClinicalCakar E, et al. 2009Prospective observationalTurkeyAS\[121\]10031.6 (10.5)9.1 (6.9)No change with work: 3.7 (3.6)Change to lighter workload: 7.3 (4.8)Permanently work-disabled: 7.8 (6.9)Clinical, economic, humanisticDincer U, et al. 2008Cross-sectionalTurkeyAS\[111\]92.7Enrollment: 33.6 (12.0)Onset: 23.2 (9.6)Diagnosis: 27.9 (11.6)10.4 (8.1)6.1 (5.1)ClinicalSlobodin G, et al. 2011Retrospective observationalIsraelAxSpA\[148\]52.3Diagnosis:Men: 35.6 (11.7) Women: 38.5 (12.3)NRMen: 5.9 (60.4) Women 5.7 (6.0)ClinicalCayetti LA, et al. 2013Prospective observationalArgentinaAS\[147\]75.5Median (IQR)46 (18--35)NRMedian (IQR)5 (2--13)Clinical, humanisticGrigg SE, et al. 2011Cross-sectionalAustraliaAS\[127\]NROnset: 23.9 (9.3)NR10.0 (8.9)Humanistic, economic*AS* ankylosing spondylitis, *axSpA* axial spondyloarthritis, *IQR* interquartile range, *NR* not reported^a^Age at study participation unless otherwise indicated

The methodological quality of each study included in the analysis is described in Supplementary Table 3. The overall scores on the quality index ranged from 5 to 17 of 27. For questions assessing study reporting, scores ranged from 3 to 8 of 11, with most studies (*n* = 16) having a score of ≥ 6. For the assessment of external validity, scores ranged from 1 to 6 of 10, with the majority of studies (*n* = 15) having a score of ≤ 4. For questions assessing internal validity, scores ranged from 0 to 3 of 6, with 12 studies having a score of 3.

Clinical Burden of Delayed Diagnosis {#Sec9}
------------------------------------

Among the 15 studies that evaluated clinical burden of delayed axSpA diagnosis, the most common measures used to assess disease activity included BASDAI (*n* = 12) \[[@CR6], [@CR35], [@CR46], [@CR51], [@CR52], [@CR55], [@CR59]--[@CR63], [@CR65]\], BASFI (*n* = 12) \[[@CR6], [@CR35], [@CR46], [@CR51], [@CR52], [@CR55], [@CR59]--[@CR63], [@CR65]\], and BASMI (*n* = 8) \[[@CR6], [@CR35], [@CR51], [@CR52], [@CR55], [@CR61], [@CR62], [@CR65]\] (Table [3](#Tab3){ref-type="table"}). A significant association was found between longer diagnosis delay and worse BASFI scores in eight of 12 studies \[[@CR6], [@CR35], [@CR46], [@CR51], [@CR59]--[@CR62]\] and worse BASMI scores in six of eight studies \[[@CR6], [@CR35], [@CR51], [@CR52], [@CR61], [@CR62]\]; however, only four of 12 studies found a significant association between longer delay and worse BASDAI scores \[[@CR6], [@CR35], [@CR46], [@CR51]\]. Additionally, one study reported that patients with delayed axSpA diagnosis responded less favorably to treatment based on BASDAI scores and the rate of radiographic progression \[[@CR46]\].Table 3Clinical impact of delayed diagnosis of axSpAStudyPatient population \[*N*\]Definition of delay, yearsClinical outcome measuresPatient outcomesNie A, et al. 2018AS\[281\]ContinuousPSQILonger delay significantly correlated with higher PSQI scores (β = 0.174; *P* = 0.001)Zhao J, et al. 2015AS\[256\]≤ 5 vs. \> 5BASRI-hipDelay of \> 5 years positively associated with more severe hip disease (OR, 2.35 \[95% CI, 1.36--4.08\]; *P* = 0.002)Seo MR, et al. 2015AxSpA\[94\]≤ 8 (late diagnosis) vs. \> 8 (early diagnosis)CRPESRBASDAIBASFIModified Schober testRadiographic sacroiliitis III or IVSpine bony changemSASSSACR functional class III or IVSignificant differences between late vs. early diagnosis at time of diagnosis: Modified Schober test: median (IQR), 2.7 (1.6--4.4) vs. 6.0 (2.5--6.0) cm; *P* = 0.03 mSASSS: median (IQR), 21.0 (3.0--42.0) vs. 0 (0--4.5); *P* \< 0.01 Proportion with spine bony changes: 77.4 vs. 44.8%; *P* \< 0.01Significant differences between late vs. early diagnosis at time of study: BASDAI: median (IQR), 3.4 (2.0--4.9) vs. 2.0 (1.0--4.2); *P* = 0.01 BASFI: median (IQR), 2.5 (0.3--3.8) vs. 0.7 (0.1--1.4); *P* \< 0.01 Modified Schober test: median (IQR), 2.8 (1.2--4.5) vs. 4.5 (3.3--5.3) cm; *P* \< 0.01 mSASSS: median (IQR), 26.0 (4.8--46.3) vs. 1.0 (0--12.5); *P* \< 0.01 Proportion with spine bony changes: 85.3 vs. 53.6%; *P* \< 0.01Aggarwal R, et al. 2009AS\[70\]≤ 5.9 vs. \> 5.9BASDAIBASFIBASMIPatients with delay of \> 5.9 years had significantly worse mean (SD) scores than those with delay of ≤ 5.9 years BASDAI: 3.7 (1.8) vs. 2.7 (1.7); *P* = 0.035 BASFI: 3.8 (2.4) vs. 2.5 (2.1); *P* = 0.033 BASMI: 3.3 (2.7) vs. 1.5 (2.2); *P* = 0.012Gunasekera W, et al. 2014AS \[106\]ContinuousBASDAIBASFIBASMIBASMI score increased by 0.06 per year of diagnosis delay (*P* = 0.0002)No significant impact of diagnosis delay on BASDAI or BASFISullivan C, et al. 2014AS\[92\]\< 4 vs. 5--9 vs. \> 10 vs. unknownBASDAIBASFIBASMINo significant differences in BASDAI, BASFI, or BASMI scoresAbdelrahman FI, Mortada M. 2018AxSpA\[126\]Mean (SD) Before 2010: 11.3 (3.9)After 2010:4.6 (2.8)BASDAIBASFIBASMIPatients with longer delay had worse mean (SD) scores than those with shorter delay (all *P* \< 0.001): BASDAI: 9.1 (1.4) vs. 4.3 (2.2) BASFI: 9.1 (1.4) vs. 3.9 (2.2) BASMI: 8.9 (1.2) vs. 2.2 (2.0)Ibn YY, et al. 2012AS\[100\]\< 5 vs. ≥ 5CRPESRBASDAIBASFIBASRIOcciput-to-wall distanceChest expansionSchober testPatients with delay of ≥ 5 years had significantly greater BASFI (61.4 vs. 51.1) and BASRI (8.4 vs. 5.7) scores and significantly lower chest expansion (2.2 vs. 3.5 cm) and Schober test result (1.7 vs. 2.8 cm) than those with delay of \< 5 years (all *P* \< 0.05)Longer diagnostic delay was significantly correlated with: Occiput-to-wall distance: *r* = 0.317 (*P* = 0.001) Chest expansion: *r* = 0.374 (*P* \> 0.001) Schober test: *r* = −0.368 (*P* \< 0.001) BASFI: *r* = 0.289 (*P* = 0.004) BASRI: *r* = 0.349 (*P* \< 0.001)No impact of diagnostic delay on BASDAI score, ESR, or CRP levelFallahi S, Jamshidi AR. 2016AS\[163\]ContinuousBASDAIBASFIBASMIChest expansionFinger-to-floor distanceIntermalleolar distanceModified Schober testCervical rotationTragus-to-wall distanceSacroiliitis gradingLonger diagnostic delay significantly correlated with worse outcomes: BASDAI: *r* = 0.18 (*P* = 0.026) BASFI: *r* = 0.23 (*P* = 0.003) BASMI: *r* = 0.41 (*P* \< 0.001) Chest expansion: *r* = −0.38 (*P* \< 0.001) Finger-to-floor distance: *r* = 0.27 (*P* \< 0.001) Intermalleolar distance: *r* = −0.18 (*P* = 0.022) Modified Schober test: *r* = −0.33 (*P *\< 0.001) Cervical rotation: *r* = −0.29 (*P* \< 0.001) Tragus-to-wall distance: *r* = 0.30 (*P* \< 0.01) Sacroiliitis grading: *r* = 0.16 (*P* = 0.042)Hajialilo M, et al. 2014AS\[60\]\< 3 vs. \> 3BASDAIBASFIPatients with delay of \> 3 years had significantly worse BASFI scores (mean \[SD\], 4.1 \[0.7\] vs. 3.3 \[1.0\]; *P* = 0.001) but comparable BASDAI scores vs. patients with delay of \< 3 yearsAlayli G, et al. 2015AS\[85\]ContinuousBASDAIBASFIBASMImSASSSDelayed diagnosis positively correlated with BASFI and BASMI scores and mSASSS but not with BASDAI scoresCakar E, et al. 2009AS\[121\]Mean (SD)No change in work: 3.7 (3.6)Work-disabled, change in job: 7.3 (4.8)Permanently work disabled: 7.8 (6.9)CRPESRBASFIBASDAIBASMIModified lumbar Schober testLateral lumbar flexionChest expansionChin-to-sternum distanceTragus-to-wall distanceIntermalleolar distancePatients with longer delay had higher CRP levels and worse mobility than those with shorter delay (mean \[SD\], no change vs. job change vs. permanently disabled): CRP, mg/L: 11.1 (8.3) vs. 17.6 (22.2) vs. 39.7 (46.4); *P* = 0.034 Modified lumbar Schober test, cm: 4.3 (1.4) vs. 3.2 (1.3) vs. 2.0 (1.5); *P* \< 0.001 Lateral lumbar flexion, cm: 18.2 (10.8) vs. 14.7 (12.7) vs. 7.8 (3.5); *P* \< 0.001 Chest expansion, cm: 5.5 (2.0) vs. 4.5 (2.1) vs. 2.4 (1.5); *P* \< 0.001 Chin-sternum distance, cm: 0.2 (0.8) vs. 1.3 (1.8) vs. 2.0 (2.4); *P* = 0.001 Tragus-to-wall distance, cm: 0.6 (1.9) vs. 1.2 (2.5) vs. 6.9 (6.2); *P* = 0.001 Intermalleolar distance, cm: 113.9 (15.3) vs. 105.3 (17.2) vs. 90.6 (21.3); *P* \< 0.001 BASFI: 3.3 (2.1) vs. 4.6 (2.1) vs. 5.2 (2.5); *P* = 0.005 BASMI: 1.1 (1.1) vs. 2.4 (1.3) vs. 4.3 (2.3); *P* \< 0.001Dincer U, et al. 2008AS\[111\]\< 3 years vs.\> 3 yearsBASDAIBASFINo significant differences in BASDAI or BASFI scoresSlobodin G, et al. 2011AxSpA\[148\]≤ 1 vs. 1--5 vs. ≥ 5CRPESRSchober testFinger-to-floor distanceOcciput-to-wall distanceChest expansionPatients with delay of \> 1 year had significantly (*P* = 0.028) greater occiput-to-wall distance (less spinal flexibility) than those diagnosed within 1 year (mean \[SD\]: ≤ 1 year, 1.5 \[5.4\] cm; 1--5 years, 3.7 \[2.0\] cm; ≥ 5 years, 2.4 \[5.3\])Cayetti LA, et al. 2013AS\[147\]≤ 3 vs. \> 3 to ≤ 10 vs. \> 10BASDAIBASFIBASMIBASRINo substantial impact of delay on functional capacity or radiographic damage*ACR* American College of Rheumatology, *AS* ankylosing spondylitis, *axSpA* axial spondyloarthritis, *BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BASFI* Bath Ankylosing Spondylitis Functional Index, *BASMI* Bath Ankylosing Spondylitis Metrology Index, *BASRI* Bath Ankylosing Spondylitis Radiology Index, *CRP* C-reactive protein, *ESR* erythrocyte sedimentation rate, *IQR* interquartile range, *mSASSS* modified Stoke Ankylosing Spondylitis Spinal Score, *PSQI* Pittsburgh Sleep Quality Index

Five studies evaluated additional measures of spinal mobility (e.g., Schober test, occiput-to-wall distance, lateral lumbar flexion); in all studies, patients with a longer diagnosis delay had worse spinal mobility than those with a shorter delay (Table [3](#Tab3){ref-type="table"}) \[[@CR6], [@CR46], [@CR59], [@CR62], [@CR64]\].

A total of six studies assessed radiographic structural progression, of which five found a significant association between longer diagnosis delay and greater radiographic progression \[[@CR6], [@CR46], [@CR50], [@CR59], [@CR61]\]; in the remaining study, there was a trend toward greater radiographic progression in patients with longer diagnosis delay, but this difference did not reach statistical significance \[[@CR65]\] (Table [3](#Tab3){ref-type="table"}). In the two studies that evaluated mSASSS, patients with a longer diagnosis delay had significantly higher mSASSS than those with a shorter delay \[[@CR46], [@CR61]\]; one study also found that patients with a longer delay had a higher mean change in mSASSS per year following diagnosis \[[@CR46]\].

Four studies assessed CRP levels and ESR \[[@CR46], [@CR59], [@CR62], [@CR64]\] (Table [3](#Tab3){ref-type="table"}). ESR was comparable between patients with early vs. late diagnosis in all studies. CRP levels were also comparable between patients with early vs. late diagnosis in three of four studies \[[@CR46], [@CR59], [@CR64]\]; however, one study found that patients with a longer delay in diagnosis had higher CRP values than those with a shorter time to diagnosis \[[@CR62]\].

Economic Burden of Delayed Diagnosis {#Sec10}
------------------------------------

The majority (six of nine) of studies that evaluated economic burden of delayed diagnosis assessed work disability or employment; in all of these studies, longer diagnosis delay was associated with a greater likelihood of work disability or unemployment \[[@CR46], [@CR52], [@CR56], [@CR58], [@CR62], [@CR66]\] (Table [4](#Tab4){ref-type="table"}). In the three studies that evaluated treatment costs and healthcare utilization, longer diagnosis delay was associated with higher costs related to doctors' visits and specialist services \[[@CR35], [@CR57]\], unnecessary spinal surgery \[[@CR35]\], and treatments \[[@CR57], [@CR66]\] (Table [4](#Tab4){ref-type="table"}).Table 4Economic impacts of delayed diagnosis of axSpAStudyPatient population \[*N*\]Definition of delay, yearsEconomic outcome measuresPatient outcomesSeo MR, et al. 2015SpA\[105\]≤ 8 vs. \> 8Social disabilities^a^Higher proportion of patients with delay of \> 8 years reported social disabilities compared with those with delay of ≤ 8 years, although the difference did not reach statistical significance (28.3 vs. 12.8%; *P* = 0.06)Gunasekera W, et al. 2014AS\[106\]ContinuousWork disabilityPatients who were work disabled had a significantly longer delay than those who were not work disabled (mean, 16.6 vs. 7.8 years; *P* = 0.005)Risk of being work disabled increased by 6.6% per year of delay (OR, 1.07 \[CI, 1.0--1.1\]; *P* = 0.0009)Sullivan C, et al. 2014AS\[92\]0--4 vs. 5--9 vs. \> 10 vs. unknownTNFi useNo relationship between diagnostic delay and likelihood of TNFi useSullivan C, FitzGerald O. 2011AS\[59\]\< 4 vs. 5--9 vs. \> 10EmploymentLonger delay was associated with greater likelihood of work disability; unemployment rose from 20 to 29% to 41% among those diagnosed in \< 4 years, 5--9 years, and \> 10 years, respectivelyMennini FS, et al. 2018AxSpA\[1084\]3 years prior to initial SpA diagnosisCost (€) of SpA-related specialist visits and treatmentsIn 3 years prior to SpA diagnosis, patients received an average of 4 specialist services and 4 treatments related to undiagnosed SpA, resulting in an average cost of ≈ €140.90 per patient, corresponding to ≈ €152,767 for study population and ≈ €5,387,972 for Italian population of patients with SpAAbdelrahman FI, Mortada M. 2018AxSpA\[126\]Mean (SD), 11.3 (3.9) vs.4.6 (2.8)Healthcare costsDoctor visitsSpinal surgeryPatients with longer delay had worse economic outcomes than those with shorter delay (all *P* \< 0.001): Cost of delay period, mean (SD): \$9879.30 (\$3827.20) vs. \$2373.90 (\$881.80) No. of doctor visits during delay period, mean (SD): 14.3 (6) vs. 5.6 (3.4) Proportion of patients with unnecessary spinal surgery: 65.4 vs. 34.6%Abdul-Sattar A, Abou El Magd S. 2017AS\[190\]ContinuousWork disabilityPatients who were work disabled had significantly longer delay than those who were not work disabled (mean \[SD\], 8 \[2.9\] vs. 4 \[2.1\] years; *P* \< 0.001)Longer delay was associated with greater likelihood of work disability (OR, 2.1 \[95% CI, 1.00--3.40\]; *P* = 0.001)Cakar E, et al. 2009AS\[121\]ContinuousWork disabilityPatients who were permanently work disabled or changed jobs due to work disability had longer mean (SD) delay (7.8 \[6.9\] and 7.3 \[4.8\] years) than those who were not work disabled (3.7 \[3.6\] years; *P* = 0.028)Grigg SE, et al. 2011AS\[127\]\< 5 vs. 5--10 vs. \> 10Treatment costs (\$)EmployabilityEstimated cost of treatment prior to diagnosis was \> \$3000 in 25.6% of patients with \< 5 years of delay vs. 44.4% with 5--10 years of delay (*P* = 0.08) and 67.4% with \> 10 years of delay (*P* = 0.002)Employability was affected in 66.7% of patients with \< 5 years of delay vs. 75.6% with 5--10 years of delay (*P* = 0.37) and 90.7% with \> 10 years of delay (*P* = 0.003)*AS* ankylosing spondylitis, *axSpA* axial spondyloarthritis, *OR* odds ratio, *SpA* spondyloarthritis, *TNFi* tumor necrosis factor inhibitor^a^Defined as job changes or the complete discontinuation of work attributable to the disease among workers, discontinued studies among students, and requiring the assistance of another person among homemakers

Humanistic Burden of Delayed Diagnosis {#Sec11}
--------------------------------------

Five of six studies found that delayed diagnosis of axSpA was associated with negative impacts on health-related quality of life \[[@CR6], [@CR53], [@CR54], [@CR62], [@CR66]\]; however, results for specific outcome measures varied across studies (Table [5](#Tab5){ref-type="table"}). Although one study found a significantly higher prevalence of physician-reported depression among patients with a diagnosis delay of ≥ 7 years among than those with a delay of \< 7 years \[[@CR54]\], two studies found no significant association between longer diagnosis delay and Beck Depression Inventory scores \[[@CR62], [@CR66]\]. Similarly, one study showed that longer diagnosis delay was significantly correlated with worse ASQOL scores and more morning stiffness \[[@CR6]\], whereas two studies showed no significant difference in ASQOL \[[@CR65]\] or morning stiffness \[[@CR62]\] between patients with a late vs. early diagnosis. Humanistic burden was assessed using the 36-item Short Form Health Survey in one study, which showed that longer diagnosis delay was associated with worse scores in the physical functioning and general health domains \[[@CR62]\]. In one study, patients reported experiencing negative psychological impacts during the delay period \[[@CR53]\]; in a separate study, patients reported feeling emotional relief and a more positive outlook regarding the disease once they received a diagnosis \[[@CR66]\].Table 5Humanistic impacts of delayed diagnosis of axSpAStudyPatient population \[*N*\]Definition of delay, yearsHumanistic outcome measuresPatient outcomesMartindale J, Goodacre L. 2014AS/AxSpA\[10\]ContinuousEmotional and social healthIn the period between symptom onset and diagnosis (mean \[SD\], 10.1 \[7.3\] years; range, 1--20 years), patients experienced negative psychological impact, including desperation, distress, depression, and feeling disheartened; employed patients felt stigmatized by the perception of a "bad back"Fitzgerald G, et al. 2017AxSpA\[564\]\< 7 vs. ≥ 7DepressionHigher prevalence of depression in patients with delay of ≥ 7 years than those with delay of \< 7 years (15.5 vs. 9.1%; *P* = 0.032)Fallahi S, Jamshidi AR. 2016AS\[163\]ContinuousASQOLFatigue^a^Morning stiffness^b^Delay positively correlated with worse ASQOL scores (*r* = 0.21; *P* = 0.008) and morning stiffness (*r* = 0.21; *P* = 0.006)Cakar E, et al. 2009AS\[121\]Mean (SD)No change in work: 3.7 (3.6)Work disabled, change in job: 7.3 (4.8)Permanently work disabled: 7.8 (6.9)Morning stiffnessBAS-GSF-36Beck Depression InventoryPatients with longer delay had worse mean (SD) scores in physical functioning and general health domains of SF-36 than those with shorter delay Physical functioning: no change, 59.96 (21.99); change in job, 43.14 (23.15); permanently disabled, 51.16 (19.95); *P* = 0.009 General health: no change, 46.00 (20.90); change in job, 33.67 (20.27); permanently disabled, 22.04 (19.99); *P* = 0.035Cayetti LA, et al. 2013AS\[147\]≤ 3 vs. \> 3 to ≤ 10 vs. \> 10ASQOLNo significant differences in ASQOL scores between groupsGrigg SE, et al. 2011AS\[127\]\< 5 vs. 5--10 vs. \> 10 yearsEmotional reliefPerception of symptomsOutlook for the futureBeck Depression InventoryOnce diagnosed, 69% experienced emotional relief, 76% experienced a positive shift in perception of symptoms, and 66% had an optimistic outlook for the futureDelay was not associated with long-term depressed mood as assessed by Beck Depression Inventory scores*AS* ankylosing spondylitis, *ASQOL* Ankylosing Spondylitis Quality of Life questionnaire, *axSpA* axial spondyloarthritis, *BAS*-*G* Bath Ankylosing Spondylitis Patient Global Score, *SF*-*36* Short Form 36^a^BASDAI question 1, visual analog scale 0--10^b^BASDAI question 5, visual analog scale 0--10

Discussion {#Sec12}
==========

A limited number of studies have evaluated the impact of delayed diagnosis on disease burden in patients with axSpA, particularly with respect to economic and humanistic outcomes. The included studies were conducted in only 13 countries, and only six countries had ≥ 1 study. Prevalence of axSpA and application of classification criteria in routine practice vary by country \[[@CR20]--[@CR22], [@CR43]\], which may influence length and burden of delay. Further studies are needed to gain a more comprehensive understanding of factors contributing to diagnosis delay and the impact of delayed diagnosis on disease burden globally and across a greater variety of practice settings.

Most of the identified studies included \< 200 patients, and the majority of patients across all studies were male and had a diagnosis of AS. Historically, axSpA has been considered a disease predominantly affecting males \[[@CR67], [@CR68]\], in part due to the perception of AS as the prototypical disease state \[[@CR21], [@CR25], [@CR30]\]. The prevalence of AS is approximately 2- to 3-fold higher in men than women \[[@CR67], [@CR68]\]. Definitive radiographic sacroiliitis and spinal damage occur less frequently in women than men \[[@CR64], [@CR69]--[@CR71]\], and women are more likely to have peripheral symptoms \[[@CR71]--[@CR75]\] and extra-articular manifestations \[[@CR71], [@CR76]--[@CR78]\]. Thus, early classification criteria that focus primarily on axial symptoms would be less likely to identify female patients with axSpA. The adoption of a broader definition of axSpA that includes peripheral features has revealed that the prevalence of axSpA may be nearly equal between men and women \[[@CR31], [@CR79], [@CR80]\] and that nonradiographic axSpA may be more common in women than men \[[@CR81]\]. Based on the available literature, there is limited information on the impact of delayed diagnosis in women or patients with nonradiographic axSpA. More research is needed to better characterize the impact of diagnosis delay on overall disease burden in these populations.

Nevertheless, the available literature indicates that delayed diagnosis of axSpA is associated with an increased burden of disease, particularly with respect to mobility and function. The majority of studies that evaluated functional limitation and spinal mobility (e.g., BASFI, BASMI) found that longer diagnosis delay was associated with worse outcomes. Similarly, most studies that assessed radiographic structural progression showed that patients with a longer delay had more radiographic damage than those with shorter time to diagnosis. Previous studies have shown that radiographic damage is correlated with physical function and spinal mobility in patients with axSpA \[[@CR82]--[@CR85]\]. Therefore, there is a need for earlier diagnosis and treatment to prevent irreversible structural damage, which may in turn result in reduced mobility and greater functional limitation.

With respect to economic burden, the majority of the available literature focused on employment and work disability. Across all included studies, longer diagnosis delay was associated with more work disability and higher rates of job changes and unemployment, which may reflect the reduced mobility and greater functional impairment in patients with a longer delay. Three studies found that delayed diagnosis of axSpA resulted in increased healthcare costs and utilization. These studies were conducted in Italy \[[@CR57]\], Egypt \[[@CR35]\], and Australia \[[@CR66]\], and two were single-center studies \[[@CR35], [@CR66]\]; thus, further research is needed to understand the impact of diagnosis delay on costs and resource utilization in a broader range of healthcare settings.

Overall, the available data suggest that delayed diagnosis of axSpA is associated with an increased humanistic burden. Although conflicting results were observed across studies for specific outcomes such as ASQOL scores and depression, ≤ 3 studies assessed any specific outcome measure, which limits the discernment of meaningful trends for any outcome. However, the majority of studies that assessed humanistic burden reported a negative impact of delayed diagnosis on ≥ 1 measure of health-related quality of life, indicating that earlier diagnosis may alleviate some of the humanistic burden of axSpA.

These findings highlight the importance of comprehensively evaluating the impact of a delay in axSpA diagnosis and its potential impact on the healthcare system. Available data from this review demonstrated that earlier diagnosis and treatment led to better management of patient outcomes and healthcare costs. More research is needed to translate the clinical and psychological effects of untreated disease and misdiagnosis on healthcare resources. Education on classification criteria to distinguish key symptoms of axSpA and the development of diagnostic criteria that can be easily and routinely applied in clinical practice may lead to timely referrals, early diagnosis, and appropriate treatment to prevent irreversible damage that may impact every aspect of a patient's life.

Limitations {#Sec13}
-----------

The definition of "delay" was widely variable among the studies, which may contribute to the differences in the impact of diagnosis delay on specific outcomes across studies. Because most of the studies included in this review were conducted across Europe and Asia, results may not be representative of all patients or healthcare systems. The majority of the studies included primarily male patients and therefore did not capture the longer delays typically experienced by female patients or account for other sex differences \[[@CR86]--[@CR92]\]. Additionally, the outcome measures used to assess economic and humanistic burden varied among the included studies. Together with the limited number of relevant studies and small patient population, these limitations precluded meaningful meta-analysis for the outcome measures assessed; thus, the results of this systematic literature review are descriptive in nature.

Conclusions {#Sec14}
===========

Overall, delayed diagnosis in patients with axSpA was associated with decreased physical function, higher direct and indirect costs, and negative psychological impacts. This study highlights the importance of early diagnosis and treatment of axSpA to improve outcomes and mitigate extensive burden on patients and society. Further efforts by the healthcare community are warranted to increase awareness of early signs of disease and reduce the delay in diagnosis of axSpA.
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